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The amount of liver involved in the disease was not 
associated with the outcome 
Conclusions: FDG-PET/CT was able to separate responders 
from non-responders about 6 weeks after RE when using 
PERCIST criteria.  
Although MTV may provide a baseline prognostic factor, in 
our experience, the MTV obtained from a manual contouring 
resulted to be inappropriate to predict the therapeutic 
response. More sophisticated segmentation methods should 
be analysed to assess the MTV usefulness. 
Overall, contrarily to CT, FDG-PET/CT about 6 weeks after 
the treatment can provide early response and survival 
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Purpose/Objective: SBRT for liver metastases has shown in 
many reports a high rates of Local Control (LC), mild toxicity, 
and a positive trend on overall survival (OS).However, many 
questions about the prognostic factors that can influence LC 
and OS are still open. In this study we analyzed our cohort of 
patients treated for CRC liver metastases by SBRT. 
Materials and Methods: Between April 2006 and February 
2014, 89 pts with 163 colorectal metastases were treated by 
SBRT. Median age was 65 ys ,with KPS >70. 45% of them had 
synchronous mets and in 79% a primary tumor was controlled, 
47 patient (52%) were treated to a single lesion and 48% pts 
to two to five mets. 85% of pts received previous 
chemotherapy. SBRT was delivered by 6MV Linac using beam 
modulator (VMAT). Median GTV volume was 20 cc (0.3-306 
cc). Dose delivered in 3 fx was prescribed to the 67% isodose 
line in 82% of lesions and to the isocenter in 17%. In 81.5 % of 
lesions the relative BED 10 was > 100 Gy. Dose constraint for 
healty liver was D700 mL< 15 Gy . Set-up and isocenter position 
was controlled before each fx using CBCT, gold markers as 
target surrogate were implanted in 78 % of pts. Respiratory 
motion was controlled by active breathing coordinator, 
breath hold technique or delineating an ITV of inhale an 
exhale CT data in 62%, 30% and 8% respectively. The response 
was evaluated 60 days after SBRT by CT and PET scan and 
every 3monyhs successively. Toxicity was assessed by CTCAE 
score. 
Results: With a median FU of 16.5 (range 5-75) months, the 
median survival was 44.4 months. 23 Pts are still alive(26%). 
LC, defined as no evidence of tumor regrowth within the 
treated lesion, was reached in 84% of lesions. Mainly relapses 
occurred outside the treated field : in 23% (21/89) of pts the 
'in field' relapses occurred in the presence of 'out of field' 
progression while single only patient relapsed in field only. 
47 (53%) through the liver and 49 (55%)outside.1 y and 2 ys LC 
was respectively 83% and 69%. On univariate analysis, better 
LC was statistically related to the use of Gold Fiducials (p< 
0,001), Breath Control (p=0.013), BED 10 >100Gy (p< 0,001) 
and prescription to 67% isodose vs isocenter (p <0,001), GTV 
volume < 14 cc (p= 0.029) . 1y and 2 ys OS were 75% and 33% 
respectively. The OS rate seems not to be related to age, the 
number of liver lesions at diagnosis, mets Synchronous, use of 
chemotherapy while better OS was related to single lesions vs 
more than one treated (p= 0.041) by SBRT. Furthermore 
improved OS was associated with no relapse through the 
liver, 1y and 2 ys OS was 88% and 45% respectively for no 
recurrence vs 64% and 23% for hepatic relapse 
(p=0.005).Acute toxicity was only gastrointestinal in 11% of 
Pts G1 and in 4% G2.  
 
Conclusions: In our experience SBRT for CRC liver mets is a 
safe and an effective ablative therapy that could be offered 
to patients not suitable to others therapies. Disease 
progression occurs mainly outside the treated field. Probably, 
limiting our sample of pts to the oligometastatic subset 
would have a greater impact on OS rates. 
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Purpose/Objective: Head and neck cancer (HNC) is the most 
common cancer in developing countries. Pain is the 
commonest symptom in HNC patients and it may be due to 
the tumour and/or cancer treatment. Previous studies have 
shown these patients to be at risk for inadequate pain 
management. This study evaluates pain and the adequacy of 
analgesic management during radiation. 
Materials and Methods: 60 patients of locally advanced head 
and neck cancers treated primarily with conventional chemo-
radiation or adjuvant radiation +/- concomitant 
chemotherapy following surgery (60-66 Gy / 30-33 # / 6 – 6.5 
weeks) were included in the study. Patients completed the 
Brief Pain Inventory (BPI) Questionnaire at time of initial 
visit, 3 weeks of CCRT/RT, at the end of treatment and at 3 
months of follow-up. Pain intensity scores were derived from 
the BPI Questionnare. 
Pain intensity scores were: 1-3 – Mild, 4-7 – Moderate, 8-10 – 
Severe. Analgesics prescribed were derived from WHO's 
'Analgesic Ladder' approach to cancer pain. Analgesic scores 
were: NSAIDS and Adjuvants – 1, Mild opioids – 2, Strong 
opioids – 3.  
The Pain Management Index (PMI) is a simple index linking 
the usual severity of cancer pain with the category of 
